12:50 PM
 | 
Jan 14, 2019
 |  BC Extra  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China.

Ascletis believes KN035 is a potential first-in-class therapy for HBV. The company told BioCentury it expects to begin Phase II testing of the...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >